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Summary: Eleven drugfree patients meetingResearch Diagnostic Criteria for Major Depressive Disorder have been treated with desipramine and given a clonidine infusion after 0, 1 and 3 weeks of treatment. The sedative and hypoten sive effects of clonidine were significantly inhibited after three weeks of treatment with desipramine: a similar interaction was seen after one week of treatment although this just failed to reach statistical significance. The growth hormone (GH) responseto clonidine was initially impaired, but increasedsignificantly after one week of treatment. A significant reduction in the GH response occurred dur ing the second and third weeks of treatment with desipramine. This last finding is interpreted as evidence of adaptive change of @ adrenoceptors : the other changes can be explained by the known ability of desipramine to block the re-uptake of noradrenaline.
The tricyclic antidepressants have many pharma cological properties including the ability to block the re-uptake of noradrenaline, of 5-hydroxy-tryptamine and in some cases of dopamine, and to block the receptors at which noradrenaline, 5-hydroxytrypt amine, dopamine, histamine and acetylcholine act (for reviews see Sulser, 1978; Sugrue, 198 Ia) . In addition to these acute effects chronic treatment with tricyclic drugs alters the number, function and circadian rhythm of a and @3 adrenoceptors and of dopamine and 5-hydroxytryptamine receptors (Creese and Sibley, 1980; Charney et a!, 1981a; Sugrue, 1981b) . However the clinical relevance of these animal findings is un certain as it is unknown which of these effects occur in clinical practice and which are necessary for the anti depressant action of tricyclic drugs.
Animal studies of the effects of antidepressant drugs upon noradrenaline have used desipramine as a relatively selective inhibitor of the re-uptake of nor adrenaline (Maitre et a!, 1980) . A single dose of desi pramine causes a potent inhibition of noradrenaline re-uptake together with a weaker blockade of post synaptic a1 adrenoceptors (U'Prichard et a!, 1978) . Three weeks of desipramine additionally leads to a reduction in the number and function of @3 adreno ceptors (for reviews see Creese and Sibley, 1980; Charney et a!, 1981a; Sugrue, 1981a and b) and of a2 adrenoceptors (Crews and Smith, 1978 and 1980; Svensson and Usdin, 1978; Tang eta!, 1978 and 1979; McMillen et a!, 1980; Sypraki and Fibiger, 1980; Sugrue, 198lc) . These slowly developing adaptive changes in a2 and @3 adrenoceptors may be relevant to the mechanisms of action of antidepressant drugs, particularly as their time course follows that of the antidepressant effect of these drugs.
To investigate whether or not similar changes in a2 adrenoceptors occur in patients treated with desi pramine, we have given such patients infusions of clonidine and have measured the effects of clonidine upon growth hormone (GH), blood pressure and sedation. As discussed previously (Checkley et a!, 1981a) it is likely that all of these effects of clonidine depend upon the stimulation of a2 adrenoceptors. Consequently if treatment with desipramine alters a2 adrenoceptors then it should alter the effects of cloni dine upon GH, blood pressure and sedatiori. We have previously shown that three weeks of treatment with desipramine inhibits the hypotensive and @sedativeeffects of clonidine (Checkley et a!, 1981b) . Recently others have replicated the inhibition by chronic desipramine treatment of the hypotensive effect of clonidine (Charney et a!, 1981b) and it has long been known that acute treatment with tricyclic antidepressants inhibits the hypotensive effect of chronic clonidine treatment (Briant et a!, 1973) . Charney also showed that chronic treatment with desipramine inhibited the ability of clonidine to suppress plasma concentrations of 3-methoxy-4-hydroxy phenylethylene glycol (MHPG) (Charney et a!, 1981b). All these findings suggest that desipramine alters the responses to the stimulation of a2 adreno ceptors in man. To investigate these phenomena further, we have now studied the interactions with clonidine after one as well as after three weeks of treatment with desipramine. As well as replicating our earlier findings we now present neuroendocrine Patients were then treated with desipramine: the initial dose of 2 mg/kg body weight was adjusted rapidly over the first week of treatment according to side effects. Clonidine tests were performed as described pre viously (Checkley eta!, 1981a) but using a smaller dose of clonidine.
Tests were performed after 0, 1 and 3 weeks of treatment with desipramine. Patients were fasted overnight and at 9.30 a.m. a catheter was inserted into a forearmvein. For 30 minutesor more no obser vations weremade.Baseline observations werethen made for 30 minutes. The clonidine (1.3 @g/km body weight) was diluted in 10 ml normal saline and in jected slowly over 10 minutes. Observations were continued for 90 minutes after starting the injection. Throughout the procedure pulse and blood pressure were recorded every 5 minutes, sedation was rated on a 5-point scale every 5 minutes and blood samples for OH estimation were taken every 15 minutes. Plasmadesipramine concentrations after I and 3 weeks of treatment were estimated using gas liquid chromatography with nitrogen detection (Braith waite, 1979) . OH estimations were made using a double antibody radioimmunoassay: any set of OH data was excluded from analysis if the baseline OH concentration exceeded 3 ng/ml. The response of each variable was plotted graphically against time and the area under the curve following injection of the drug calculated. Paired comparisons were made using Wilcoxon's signed Rank Test.
Results
The 11 patients included 4 females. The mean age of the group was 39.7 years (range 23â€"62); 9 met clinical and research diagnostic criteria (Spitzer ci' a!, 1977) for endogenous depression and 6 had diagnostic scores in the endogenous range on the Carney, Roth, Garside (1965) questionnaire. Their mean Hamilton rating score was 21 (range 13â€"33)before treatment, 13 (range 0â€"31)after one week of treatment and 10 (range 0â€"24) after three weeks of treatment with desi pramine. The mean plasma desipramine concen tration was 88.5 @.&g/l (range 31â€"265)after one week and 132 pg/I (range 28-560) after three weeks of treat ment. The following interactions were unrelated to plasma desipramine concentrations.
Prior to treatment with desipramine, the growth hormone response to clonidine was impaired (Fig 1) as has been described previously (Matussek et a!, 1980; Checkley et a!, 1981a) . After one week's treatment with desipramine growth hormone release was signi ficantly enhanced (P <.025). Between one and three weeks' treatment with desipramine, the growth hor mone response became attenuated (P <0.025), and after three weeks of treatment the GH response to clonidine was no longer significantly greater than before treatment. The response seen after one week of treatment was similar to that of normal subjects (Checkley eta!, 1981a). The hypotensive effects of clonidine are shown in Figs 2 and 3. In untreated depressed patients clonidine exerted its usual hypotensive effect and this effect was inhibited after one and three weeks of treatment with desipramine. After one week of treatment there was an inhibition of the fall in systolic blood pressure which just failed to reach statistical significance (P <.054): after three weeksoftreatment thefall in both systolic (P <.042) and diastolic (P <.05) blood pressure was inhibited.
Observer ratings of sedation are shown in Fig 4. The sedative effective of clonidine was inhibited after three weeks' treatment with desipramine (P <.01).
Discussion
This report confirms our previous finding that three weeks of treatment with desipramine inhibits the sedative and hypotensive effects of clonidine and we now report similar interactions after only one week of treatment. The fact that no further change occurs during the second and third weeks of treatment suggests that these effects are due to an acute drug effect and not to a chronic adaptive change. Similar interactions between clonidine and desipramine have been demonstrated in brain slices from which the stimulus-evoked release of labelled noradrenaline can Fia 2.â€"Mean systolic and diastolic blood pressure (Â±SEM)following a clonidine infusion in 11 depressed patients before and after one week of treatment with desipramine.
be measured (Pelayoeta!,1980) . In thispreparation clonidine reduces the release of noradrenaline, presumably by stimulating pre-synaptic oc adreno ceptors whose function is to inhibit noradrenaline release. Under the same conditions desipramine increases the release of noradrenaline from brain slices, presumably as a result of uptake blockade. It follows that desipramine should inhibit the effect of clonidine upon noradrenaline release, and this has been demonstrated (Pelayo ci' a!, 1980) . A similar interaction between clonidine and desipramine would explain how in our patients desipramine inhibits the sedative and hypotensive effects of clonidine. changed in depressed patients who recovered following treatment with ECT (Slade and Checkley, 1980) . One strength of this neuroendocrine approach to psycho pharmacology is the fact that very similar neuro endocrine testing is possible both in patients and in experimental animals as we have shown in our studies on the effects of ECT upon the GH response to clonidine in patients (Slade and Checkley, 1980) and baboons (McWilliam et a!, 1981) . The above explan ations for our present findings are now amenable to test in similar animal experiments. adrenaline release in the hypothalamus may be linked with the OH response to clonidine. If this is so then treatment with desipramine should enhance the effect of clonidine upon the release of both noradrenaline in the hypothalamus and of GH from the pituitary.
All of the interactions which have been discussed so far may be attributed to the inhibition by desipramine of the re-uptake of noradrenaline and adaptive responses at @ adrenoceptors need not be involved. However the concept of adaptive change at receptors is needed to explain our neuroendocrme findings. We have previously explained reduced OH responses to clonidine in untreated depressed patients by an cc adrenergic defect (Checkley, 1980; Checkley et a!, 1981a) . We have also explained the striking increase in the OH response to clonidine after one week of desi pramine treatment (Fig 1) as an effect of inhibition of noradrenaline re-uptake. The third neuroendocrine finding is the attenuation of this increase in the OH response to clonidine during the second and third weeks of treatment with desipramine (Fig 1) . The simplest explanation for this finding is a down regulation of the cc2adrenoceptors at which clonidine acts to release OH. Interestingly, such an adaptive mechanism reduces but does not reverse the primary effect of desipramine upon the OH response to clonidine.
This discussion has been restricted to the simplest of the explanations for our findings. It would seem un likely that clinical change has contributed to the results as the OH response to clonidine was not 
